CytomX Therapeutics, Inc. Common Stock (NASDAQ: CTMX) last traded at $2.42, down 5.84% on the session. The quote above updates while this page is open; the figures below are drawn from CytomX Therapeutics, Inc. Common Stock’s own filings and are restated only when a new one is published.
CytomX Therapeutics, Inc. Common Stock trades on NASDAQ under the ticker CTMX. Its market capitalisation is $527.32 million.
Valuation measures for CytomX Therapeutics, Inc. Common Stock, derived from the latest quote and its most recent SEC filing.
| Market cap | $527.32M |
|---|---|
| Enterprise value | $589.25M |
| Price / sales | 28.81 |
| Price / book | 1.75 |
| Beta | 1.85 |
Trailing-twelve-month figures tagged in CytomX Therapeutics, Inc. Common Stock's XBRL filings with the SEC.
| Revenue (TTM) | $18.30M |
|---|---|
| Net income (TTM) | -$79.65M |
| Operating margin | -476.19% |
| Return on equity | -26.37% |
| Cash | $17.22M |
Range and volume for CTMX over the past 52 weeks.
| 52-week high | $8.21 |
|---|---|
| 52-week low | $2.41 |
| Volume | 2.46M |
| Average volume | 3.36M |
| Previous close | $2.57 |
Invest a chosen dollar amount in CytomX Therapeutics, Inc. Common Stock with fractional shares.
Start investingCreate an account
Investing involves risk, including possible loss of principal. Nothing here is investment advice or a recommendation to buy or sell CTMX.
A dash means FurlPay does not have that figure, not that it is zero. Nothing on this page is investment advice or a recommendation to buy or sell any security. Figures are provided for information only and may be delayed or restated.